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Abstract
Background: Mucopolysaccharidosis type I (MPS-I) is a lysosomal storage disorder
caused by a deficiency of the enzyme α-L-iduronidase, leading to accumulation of
undegraded dermatan and heparan sulfates in the cells and secondary multiorgan
dysfunction. In humans, depending upon the nature of the underlying mutation(s) in
the IDUA gene, the condition presents with a spectrum of clinical severity.
Objectives: To characterize the clinical and biochemical phenotypes, and the geno-
type of a family of Golden Retriever dogs.
Animals: Two affected siblings and 11 related dogs.
Methods: Family study. Urine metabolic screening and leucocyte lysosomal enzyme
activity assays were performed for biochemical characterization. Whole genome
sequencing was used to identify the causal mutation.
Results: The clinical signs shown by the proband resemble the human attenuated form
of the disease, with a dysmorphic appearance, musculoskeletal, ocular and cardiac
defects, and survival to adulthood. Urinary metabolic studies identified high levels of
dermatan sulfate, heparan sulfate, and heparin. Lysosomal enzyme activities demon-
strated deficiency in α-L-iduronidase activity in leucocytes. Genome sequencing revealed
a novel homozygous deletion of 287 bp resulting in full deletion of exon 10 of the IDUA
gene (NC_006585.3(NM_001313883.1):c.1400-76_1521+89del). Treatment with pen-
tosan polyphosphate improved the clinical signs until euthanasia at 4.5 years.
Conclusion and Clinical Importance: Analysis of the genotype/phenotype correlation
in this dog family suggests that dogs with MPS-I could have a less severe phenotype
than humans, even in the presence of severe mutations. Treatment with pentosan
polyphosphate should be considered in dogs with MPS-I.
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1 | INTRODUCTION
Mucopolysaccharidoses (MPS) are a group of inherited lysosomal stor-
age disorders (LSDs) characterized by a deficit in lysosomal enzymes
necessary for the catabolism of glycosaminoglycans (GAGs). Accumu-
lation of undegraded or partly degraded GAGs in the cells results in
progressive multiple organ involvement. To date, deficiencies in
11 lysosomal enzymes have been identified, leading to 7 different
subtypes of MPS.1 These share common clinical features, although
the degree of severity varies between, but also within, each MPS sub-
type. The most frequent findings include coarse facial features, a short
stature, progressive skeletal disorders, organomegaly, corneal clouding
and progressive neurological signs.1,2
MPS type I is the most frequent form of MPS, affecting 1 in
100 000 live births. It occurs secondary to a deficiency in the lyso-
somal enzyme α-L-iduronidase, leading to the accumulation of
dermatan sulfate and heparan sulfates. It has historically been classi-
fied in 3 syndromes depending on the severity of the clinical signs,
although overlap exists between this spectrum of phenotypes.
Although recent therapies can improve life expectancy, quality of life,
or both, there is still no cure for these disorders and alternative treat-
ments remain desperately needed. For this, animal models of the dis-
ease have been playing a crucial role in the better understanding of
the pathophysiology of the disease and in the development of
advanced therapies.
Various naturally occurring forms of MPS have been described in
veterinary medicine including in the dog (MPS I, II, IIIA, IIIB, VI, VII),3-9
cat (MPS I, VI, VII),10-12 farm animals (MPS IIIB and IIID),13,14 and emus
(MPS IIIB)15; research colonies have been established for some of
MPS subtypes and are currently used as animal models of their human
counterparts.16,17
We describe here the clinicopathologic findings of naturally
occurring MPS-I in a Golden Retriever family, which we found to be
caused by a full deletion of exon 10 of the gene coding for alpha-L-
iduronidase (IDUA).
2 | MATERIAL AND METHODS
2.1 | Animal cases and ethical statement
The proband was presented to the University of Glasgow Small Ani-
mal Hospital for chronic diarrhea, weight loss and dysmorphism. Diag-
nostic investigations were performed as part of clinical procedures. A
female littermate of the proband had previously been presented to
the same institution for orthopedic signs and dysmorphism, for which
no diagnosis was achieved, and she was soon thereafter euthanized at
her owner request and no necropsy was performed. The breeder of
the affected dogs and the owners of related dogs were contacted and
agreed to provide DNA samples (cheek swabs) and pedigree informa-
tion from their animals (Figure 1). The study was approved by the local
ethical committee (University of Glasgow, School of Veterinary
Medicine—Form ref 55a/15).
2.2 | Clinical investigations
Routine investigations included CBC, routine blood biochemistry, uri-
nalysis, fecal culture, and diagnostic imaging tests (abdominal and car-
diac ultrasound examinations and thoracic radiographs).
2.3 | Urinary metabolic studies and leucocyte
lysosomal enzyme activities
Glycosaminoglycans were measured in the urine of the proband and a
normal control dog for comparison. Urinary glycosaminoglycan con-
centration was determined using a colorimetric protocol as previously
described.18 Briefly glycosaminoglycans (GAGs) form complex mole-
cules in the presence of the dye 1,9-dimethylmethylene blue (Sigma,
UK) in acid solution. This produces a color change from blue to pink,
which can be quantified at 520 nm against a standard of known con-
centration. Extracted GAGs were analyzed by 2-dimensional electro-
phoresis on cellulose acetate membranes and then visualized by
staining with 0.05% alcian blue stain (Sigma, UK) to differentiate sul-
fated glycosaminoglycan patterns as previously described.19
Oligosaccharide and sialic acid analysis of urine was performed by
thin layer chromatography (TLC) using a previously published proto-
col.20 Urine oligosaccharides were separated on thin layer slica gel
plates using a mobile phase of butanol/acetic acid/water (ratio
2 : 1 : 1) and then visualized by 0.2% orcinol and heat 100C. Urine
sialic acids were separated on thin layer slica gel plates using an initial
mobile phase of butanol/acetic acid/water (ratio 2 : 1 : 1) followed by
propan-1-ol/nitromethane/water (ratio 5 : 4 : 3) and then visualized
by 0.2% recorcinol and heat 100C.
The activities of lysosomal enzymes were measured in leucocytes
from the proband and a normal control dog using commercially avail-
able 4-methylumbelliferyl substrates (Glycosynth, UK). The activity of
α-L-iduronidase was measured in leucocytes using 2 mM
4-methylumbelliferyl-α-L-iduronide (Glycosynth, UK) in 0.4 M formate
buffer pH 3.5 containing 0.9% sodium chloride, using the previously
published protocol.21 Arylsulfatase B activity was measured in
leucocytes with 4-methylumbelliferyl-sulfate (Glycosynth, UK)
5 mg/mL in 0.1 M acetate buffer pH 5.4 according to the previously
published protocol.22 The activity of β-glucuronidase was measured in
leucocytes using the substrate 5 mM 4-methylumbelliferyl-β-D-
glucuronide (Glycosynth, UK) in 0.1 M acetate buffer pH 4.0. Briefly
sample lysate 10 μL was incubated with 20 μL substrate for
15 minutes at 37C. The reaction was terminated by the addition of
0.2 M carbonate buffer pH 9.5.
For each assay all incubations were performed at 37C, and in
each case the liberated 4-methylumbelliferone (4-MU) was measured
using a LS55 luminescence spectrophotometer set at emission wave-
length 450 nm and excitation wavelength 360 nm (PerkinElmer),
against a 4-methylumbelliferone standard of known concentration
(Sigma). The total protein was measured in cell lysate supernatants
using the standard Lowry total protein assay and all enzyme activities
were expressed as nmol 4-MU generated/mg total protein/hour.
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2.4 | Postmortem analysis
Following euthanasia, a full postmortem examination was performed.
Representative samples from the lungs, spleen, kidney, urinary blad-
der, liver, heart and pericardium, adrenal gland, pancreas, thyroid,
tongue, gastrointestinal tract, prostate, testis, skin, sciatic and vagus
nerves, brain (multiple sections) and eye were fixed in 10% buffered
formalin and snap frozen in isopentane chilled in liquid nitrogen. Slices
of formalin-fixed samples were then routinely processed and embed-
ded in paraffin before sectioning and staining with hematoxylin and
eosin (H&E). Additionally, formalin-fixed tissue was also cut as frozen
sections and stained with Oil Red O, Luxol fast blue (LFB) and periodic
acid-Schiff stain (PAS).
2.5 | Molecular analysis
DNA from the affected animal was extracted from blood using a
DNeasy Blood and Tissue kit (Qiagen, Crawley, UK). For the family
relatives, DNA was extracted from cheek swabs using Gentra Pur-
egene Buccal Cell Kit (Qiagen, Crawley, UK). Following PCR amplifica-
tion (see Table S1), purification of the PCR products was performed
using ExoSAP-IT (USB), before direct Sanger sequencing of both
strands using BigDye Terminator v.3.1 chemistry v.3.1 (Applied Bio-
systems) and an ABI 3730XL Genetic Analyzer (Applied Biosystems).
Sequencing traces were analyzed with Sequencher software v.4.2
(Gene Codes). However, due to the very high GC content of the
region, some exons could not be amplified by PCR or Sanger sequenc-
ing (see Table S1) and whole-genome sequencing was then carried
out by the Edinburgh Genomics laboratories, University of Edinburgh,
using Illumina HiSeq X. Sequence alignment was performed against
the dog genome reference CanFam3.1 using bwa23 and the region
corresponding to the IDUA gene was analyzed using IGV-Integrative
Genome Viewer. The sequence has been deposited to the European
Variant Archive under project ID PRJEB38456. Genotyping of family
members was performed by PCR. Primers for PCR were as follow:
Forward GCCACCGTGCTGCTCTAC; Reverse CATCCGACCACACCA-
AAAG. PCR was carried using a GC-RICH PCR system (Roche, Mann-
heim, Germany; Cat. No. 12140 306001) at the following reagent
concentrations (200 μM each dNTP, 0.2 μM of each primer, 0.8 M
GC-RICH resolution solution, 1X GC-RICH PCR Reaction buffer with
DMSO [1.5 mM MgCl2], and 1 U/25 μL of GC-RICH PCR System
enzyme mix). Thermal cycling consisted of 5 minutes at 94, followed
by 20 touchdown cycles (94 for 15 seconds, 62-0.5 at each cycle
for 30 seconds, and 72 for 30 seconds), then followed by 10 further
cycles (94 for 15 seconds, 52 for 30 seconds, and 72 for 30 sec-
onds), and a final elongation stage of 72 for 5 minutes.
In addition, the genomes of 548 dogs from 107 dog breeds were
screened for this specific variant24 (see Table S2 for further informa-
tion on the dog breeds).
3 | RESULTS
3.1 | Clinical history and examination
A 3 year and 6 month-old male Golden Retriever was presented to
the Small Animal Hospital at the University of Glasgow with an
F IGURE 1 Pedigree of the
affected dogs. Squares represent
males and circle females. Affected
individuals are depicted with the
plain black symbols with the
arrow highlighting the proband
and black circle representing the
suspected affected littermate (not
genetically tested). Unaffected
animals are represented with the
white symbols. The genotype of
the individuals is noted below
each symbol: +/+ for dogs
homozygous for the wild-type
allele, +/− for heterozygous dogs,
−/− for dogs homozygous for the
variant lacking exon 10, and ? for
nontested dogs
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8-month history of diarrhea and weight loss and a long-standing history
of dysmorphism. On presentation, the dog was alert and responsive but
was markedly underweight (body condition score 2/9; body weight
21 kg). General examination revealed a dysmorphic appearance
(Figure 2A); the proband was subjectively smaller than his littermates
and had a disproportionately large head and tongue, prognathism, and a
curved muzzle (Figure 2B). Excessive amount of soft tissue was also
noted on the left caudal aspect of the tongue. On cardiac auscultation, a
1/6 systolic murmur with split S2 and occasional premature beats with
pulse deficit were noted. The dog was also suffering from lipid deposits
in both eyes (Figure 2C) and interdigital cysts between the fourth and
fifth digits in all limbs (Figure 2D). Abnormal findings on neurological
examination consisted in bilateral positional ventral strabismus and nys-
tagmus (of variable direction). This dog originated from a litter of
8 puppies, of which a female littermate was euthanized a few months
earlier. She exhibited similar dysmorphic changes and corneal lipid
deposits; however, no diagnosis was achieved at that time. In both dogs,
abnormal limb conformation was first noted by the breeder from the age
of 3 to 4 months, and in the euthanized bitch multiple joint laxities (carpi
and stifles) were noted by a veterinary orthopedic surgeon when she
was 9 months old.
3.2 | Clinical investigations
No abnormality was detected on routine CBC. Abnormalities in serum bio-
chemistry profile included a mildly decreased albumin (2.6 g/dL—reference
interval [RI]: 2.9-3.6), a moderately raised urea (93 mg/dL—RI: 15-51;
15.5 mmol/L—RI: 2.5-8.5) with normal creatinine and a raised alanine ami-
notransferase (ALT) (371 IU/L—RI: <90 IU/L). Serum trypsin-like immuno-
reactivity (TLI), folate, cobalamin, adrenocorticotropic hormone (ACTH)
stimulation test, thyroid function tests (TT4 and cTSH) were within normal
limits. Urinalysis showed a urinary specific gravity of 1.032, presence of
microscopic blood and a urinary protein to creatinine ratio of 0.36 (normal
<0.2; 0.2 to 0.5 is considered borderline proteinuric25). Fecal culture
detected the presence of Campylobacter upsaliensis of unknown/question-
able clinical relevance. Thoracic radiographs did not reveal any substantial
abnormality with the exception of a mild generalized osteopenia and mild
vertebral changes (Figure 3C). Abdominal ultrasonography showed a
hepatosplenomegaly, absence of a left kidney and presence of sediment/
small calculi within the urinary bladder.
Echocardiography revealed severe thickening of mitral valve leaf-
lets, all aortic leaflets and the tricuspid septal leaflet (Figure 3A,B). A
left ventricular diastolic dysfunction was diagnosed based on presence
of mitral inflow and abnormal relaxation pattern on the tissular Dopp-
ler imaging (TDI). Systolic function was adequate (fractional shorten-
ing 29%: reference interval: 27-55).26
3.3 | Biochemical confirmation of diagnosis
Quantification of urinary oligosaccharides and sialic acid was within
normal limits.
Urinary glycosaminoglycan analysis revealed a marked increase in
concentrations of dermatan and heparan sulfates (Figure S1).
The activities of the relevant lysosomal enzymes are shown in
Table 1. The marked deficiency in α-L-iduronidase activity, reduced to
1.3% of the normal control dog activity, was consistent with a diagno-
sis of MPS-I. Since a biochemical diagnosis of MPS-I had been
established, the activity of iduronate-2-sulfatase was not measured.
3.4 | Treatment and outcome
Initial symptomatic treatment for the chronic weight loss and diarrhea
consisted in a 2-week course of amoxicillin/clavulanate (Synulox,
Zoetis UK) and a dietary change to a hydrolyzed diet (Purina HA,
Nestlé Purina Petcare), which resulted in a resolution of the diarrhea
and an improvement in demeanor. Following diagnosis of MPS-I, sup-
plementation with pentosan polyphosphate (PPS) (Cartrophen Vet
100 mg/mL solution for Injection, Biopharm Australia; 3 mg/kg
weekly subcutaneous injections) was started and resulted in subjec-
tive improvement in pelvic limb strength. Due to the possible interfer-
ence of PPS with the coagulation pathways, coagulation times were
monitored but remained within normal limits. Cardiac function was
reevaluated 3 months after the first scan and showed similar valvular
changes but a worsening of the systolic function (fractional shorten-
ing: 15%). Nine months after initial presentation, the dog's quality of
life deteriorated; he had become more exercise intolerant and weaker.
Body weight had decreased to 20.4 kg. Infection of the interdigital
cysts resulted in left forelimb lameness; neurological examination was
unchanged. The owner elected for euthanasia when the dog was
4.5 years old.
3.5 | Gross, histopathological, and
immunohistochemical findings
Gross postmortem examination confirmed previously identified
abnormalities in the live dog, the most relevant ones being follicular
cysts between digits 4 and 5, the bilateral corneal deposits, the lack of
a left kidney (with presence of a blind-ending left ureter), the hepato-
megaly and the firm growth extending from the ventral oral mucosa
on the left side of the tongue. All cardiac valves were thickened, with
such changes more pronounced in the atrioventricular valves of both
sides when compared to the semilunar valves (Figure 4A). Bilaterally,
the vagus nerves appeared thickened and firm. The prostate gland
was symmetrically and mildly to moderately enlarged.
The histological changes were consistent with a common pattern
of accumulation of myxomatous material and fibrosis. These myxoma-
tous changes were most evident in all heart valves, the presumed
vagus nerves (histologically no nervous tissue was appreciable any-
more), parts of the sciatic nerve and predominantly the tunica intima,
less so the tunica media of large vessels, whereas fibrosis was evident
in the pulmonary pleura, the pericardium, the epicardium, the lep-
tomeninges, the adrenal cortex and also the medulla of the peripheral
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lymph node examined. Numerous organs, including the spleen, kidney,
urinary bladder, liver, gastrointestinal system, lymph nodes, skin,
nerves, leptomeninges, cornea, and also the collagenous tissue for-
ming growths extending from the tongue and overlying the epicar-
dium contained foamy macrophages (Figure S2). Additionally,
numerous cells, including tubular epithelial cells, urothelial cells, biliary
and pancreatic ductular epithelium, apocrine gland epithelium,
adrenal cortical cells, hepatocytes, smooth muscle myofibres of large
heart and mesenteric arteries, Leydig (interstitial) cells, Schwann cells/
myelin and neurons appeared vacuolated. More specifically,
well-appreciable cytoplasmic vacuolation was observed in individual
neurons of the temporal, occipital and frontal cortex, large neurons of
the caudate nucleus and neurons of the caudal colliculi, and in larger
numbers of neurons of the thalamic nuclei, lateral and medial genicu-
late nuclei, the Purkinje cells (Figure 5B) and ventral horn nuclei. How-
ever, no appreciable vacuolation was observed in neurons of the
piriforme lobe, the hippocampus, the rostral colliculi, the pontine
nuclei, the dorsal horn and autonomic ganglia. In addition to the neu-
ronal vacuolation, the most prominent histological changes observed
in the brain consisted in a moderate to marked diffuse Purkinje cell
loss of the cerebellum (Figure 5A).
Staining of vacuolated cells with Oil Red O, PAS, Toluidine Blue
and LFB was inconsistent both on routinely processed and frozen sec-
tions of fixed tissue. With Oil Red O, cytoplasmic staining of the mac-
rophages in the spleen (Figure S2), but no other organ was observed,
while with PAS and LFB, renal, splenic and leptomeningeal macro-
phages and also cortical neurons, Purkinje cells (Figure 5C,D) and neu-
rons of the medulla oblongata variably exhibited a cytoplasmic stain.
With Toluidine Blue, some macrophages in the vagus nerve stained.
The vacuolated myofibres of large vessels and vacuolated hepatocytes
throughout failed to be stained by special stains even when con-
ducted on frozen sections.
Staining with Alcian Blue was more consistent and confirmed the
deposition of myxomatous material observed both grossly and histo-
logically in large vessels, large nerves and heart valves. Macrophages
in the spleen and cerebral leptomeninges also contained mildly Alcian
Blue-positive foamy material. Sciatic and vagus nerves showed
multifocal (sciatic; Figure 4C) to diffuse (vagus) myxomatous degener-
ation, with replacement of the axons and Schwann cells by myxoma-
tous ground substance (Alcian Blue positive) and foamy macrophages.
The polypoid growth extending from the left ventral aspect of the
tongue consisted of large amounts of poorly to moderately cellular
F IGURE 2 Photographs of the proband. A, Note the generalized muscle wastage. B, Facial dysmorphism was apparent with a curved muzzle
highlighted by the red line drawn above. Mandibular prognatism was also evident. C, Lipidic corneal deposits, which were present bilaterally. D,
Interdigital follicular cyst
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collagen reminiscent of a (early) collagenous hamartoma. Other main
histological abnormalities comprised a marked diffuse centrilobular
hepatocellular lipidosis and a moderate, multifocal, chronic cortical
fibrosis of the right kidney. Although a left ureter was present, there
was no evidence of kidney tissue on that side. The seminiferous
tubules of the testicles multifocally exhibited a marked reduction in
number of spermatogonia; overall, only few spermatids were seen.
The interstitial Leydig cells were also vacuolated (Figure 4D). Finally,
histological changes consistent with prostatic hyperplasia were
observed.
3.6 | Genetic analysis
We initially aimed to sequence all exons of the IDUA gene by Sanger
sequencing. Exons 1 to 8, 13 and 14 did not show any variant com-
pared to the dog reference genome (CanFam3.1). A synonymous vari-
ant was detected in exon 12. Amplification of the region containing
exons 10 to 11 strongly suggested a homozygous deletion of the
entire exon 10. However, as exon 9 could not be amplified and taking
in consideration the overall extremely high GC content of the whole
region of the IDUA gene, it was decided to proceed to a full genome
sequencing to prove the authenticity of the deletion and for better
identification of the deletion boundaries. Whole genome sequencing
confirmed a 287 bp homozygous deletion resulting in the full deletion
of exon 10 (NC_006585.3(NM_001313883.1):c.1400-76_1521
+89del); NC_006585.3:g.91523238_91523524del (Figure 6). Amplifi-
cation of this region by PCR in the available relatives confirmed segre-
gation of the mutation within the family with both unaffected parents
being heterozygous for the mutation (Figure 1).
This large deletion is predicted to result in a frame shift leading to
a change in protein sequence from amino acid 468 and a truncated
protein due to a premature codon stop (528 aa vs 655)
(NP_001300812.1:p.(Gly467_Glu507del)). We also screened a large
population of 548 dogs of various breeds for this variant (Table S2).
The variant was not found in any of the analyzed dog genomes.
4 | DISCUSSION
In this study, we describe a Golden Retriever family affected by MPS-I
secondary to a full deletion of the IDUA exon 10. The proband
F IGURE 3 Echocardiographic and radiographic findings. A, Right parasternal long axis image showing marked thickening of the septal mitral
valve leaflet (cursors). B, Left parasternal 4-chamber image showing marked thickening of the septal tricuspid valve leaflet (cursor). C, Right lateral
thoracic radiograph. Note the midthoracic spondylosis with possible fusion of T5/T6 and the irregular shape of T6/T7 endplates. There is a mild
decrease in bone density along the vertebrae with some thinning of the humeral cortices
TABLE 1 Activities of the relevant
lysosomal enzymes measured in the
leucocytes of the affected dog compared
to a normal control dog and a normal
human population
Enzyme activity (nmol/mg/h)
Enzyme Disorder Affected dog Control dog Human reference range
α-L-Iduronidase MPS I 0.07 5.2 10-50
Arylsulfatase B MPS VI 10 7 >5
β-Glucuronidase MPS VII 130 169 100-800
Note: A marked deficiency in α-L-iduronidase was observed, consistent with a diagnosis of MPS-I.
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presented with a chronic history of dysmorphism and recent gastroin-
testinal symptoms. The short stature and dysmorphism combined with
the clinical findings of corneal deposits, hepatomegaly, and marked
cardiac valvular changes was strongly suggestive of MPS. Diagnosis of
MPS-I was confirmed by accumulation of dermatan and heparan sul-
fates in urine and low enzymatic activity of α-L-iduronidase in
leucocytes.
Mucopolysaccharidoses are a group of inherited LSDs character-
ized by defective lysosomal enzymes, resulting in progressive accumu-
lation of GAGs in the cells of various tissues.1,27 Identification of
elevated urinary GAGs is a useful screening test; however, as
dermatan sulfate and heparan sulfate also accumulate in MPS II, VI
and VII, confirmatory diagnosis of MPS is typically obtained by testing
enzyme activity in leucocytes (in this case α-L-iduronidase). Once a
diagnosis is obtained, molecular characterization of the mutation can
be performed. Here, characterization of the mutation was initially
sought by Sanger sequencing the IDUA gene. However, considering
the extremely high GC content of the region (over 80% for some
exons), PCR amplification of 1 of the exons could not be achieved.
Moreover, as we could not completely exclude—although very
unlikely—that the strongly suspected full deletion of exon 10 could be
an artifact due to the high GC content of the region, we confirmed
the deletion by using another sequencing technique (whole genome
sequencing). We identified a new mutation, which affects the reading
frame from amino acid 468 and is predicted to result in a truncated
mutant protein of 528 amino acids, with modification/loss of the last
187 amino acids of the normal protein. However, these predictions
need to be considered carefully without further analysis of the mRNA
transcript or protein. Indeed, we cannot exclude for the aberrant tran-
script to be quickly degraded or for alternative splicing to occur.
Although at this stage the prevalence of this mutation in the Golden
Retriever breed remains unknown, screening before breeding could
F IGURE 4 Pathological findings. A, Gross pathology of the heart. Note the moderately to markedly thickened mitral valves (asterisks). B, Light
microscopic view of a section through the thickened mitral valves. H&E stain. C, Light microscopic view of a transverse section of the sciatic
nerve (major fascicles marked with asterisks). Alcian Blue stain. There is moderate accumulation of interstitial myxomatous material combined
with a conspicuous dispersion and loss of myelinated nerve fibers. The inset show a higher magnification of the sciatic nerve fascicle on the far
right. D, Light microscopic view of a testicular section. H&E stain. Multifocally, the seminiferous tubes exhibit a marked hypocellularity (asterisks),
interpreted to represent a lack of spermatogonia of all stages with a preservation of Sertoli cells (thin arrows). The Leydig cells (thick arrows)
throughout are vacuolated
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be considered to progressively eradicate this variant from the
population.
The histological findings were in line with those previously
described in the animal models of MPS-I (ie, the Plott Hound dog
model,7,28 the feline model,29 and the genetically engineered murine
knock-out model30) as well as those described in affected humans.31
Staining of the storage material with PAS, Alcian Blue and Toluidine
Blue proved to be variable and inconsistent, in line with previous
reports in various types of MPS.7,15,32-34 This could be attributed to
the heterogeneity of the storage material,15,34 the water-solubility of
GAGs4,31 and to the fact that the staining of mucins is overall very
variable depending on their degree of acidity.35,36
In humans, MPS-I (OMIM #252800) is the most frequent form of
MPS but remains overall a rare syndrome with a prevalence of 1 in
100 000 live births.37 Depending upon the severity of the clinical
signs, age at onset and life expectancy, 3 forms have been historically
defined.37,38 Hurler syndrome (MIM #607014) is the most severe
form with a diagnosis usually made within the first year of life. Typical
signs include coarsening of facial features, progressive skeletal
dysplasia, hepatosplenomegaly, corneal clouding, marked cardiac val-
vular changes and severe intellectual disability. Death frequently
occurs within the first 10 years of life due to cardiorespiratory failure
secondary to cardiac arrhythmias, or coronary artery disease. In the
mildest form of MPS-I, also known as Scheie syndrome (MIM
#607016), patients have normal or near normal intellectual capabili-
ties, but frequently suffer from cardiac, ophthalmological and skeletal
malformations. These patients usually have a near normal life expec-
tancy. An intermediate form is referred to as Hurler-Scheie syndrome
(MIM #607015), with affected patients typically surviving to adult-
hood.37-39 Nowadays, it is acknowledged that these 3 forms represent
a continuous spectrum of clinical signs, with no strict biochemical or
molecular diagnostic criteria available to separate them4,38,40-42; con-
sequently, individuals are more and more classified into severe
(Hurler) and attenuated (Hurler-Scheie, Scheie) forms.38 Although
some degree of genotype–phenotype correlation is established for
the most frequently observed variants, it remains difficult to predict
the effect of the more “unique” mutations.38,41 While patients with a
nonsense mutation on both alleles will almost invariably develop a
F IGURE 5 Light microscopic images of the cerebellum. A, There is a moderate to marked decrease in the number of Purkinje cells (arrows).
Low magnification. H&E stain. B, At higher magnification, many of the remaining Purkinje cells exhibit fine intracytoplasmic vacuoles (H&E stain),
which stain positive with periodic acid-Schiff (PAS), C and Luxol fast blue (LFB), D
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severe phenotype, the effects of less severe mutations, such as amino
acid substitutions, are more difficult to prognosticate.43 More work is
being done in that field of genoype-phenotype correlation including
trying to predict the effect of “private” mutations using in silico tools
such as independent function prediction scores and ensemble
scores.44-46 This is particularly important as most of the identified
mutations are “unique” and estimating the effect of a mutation on the
phenotype of a newborn child has relevant consequences in terms of
therapeutic options.43,44,47 Over 200 pathogenic variants are cur-
rently indexed on the Human Gene Mutation database. Most variants
are single point mutations48 and until recently, no whole exon or full
gene deletion had been described.46,49 Therefore, when looking for
new mutations in a human patient, the possibility of a full exon dele-
tion should be borne in mind especially when determining the most
suitable technique for genetic analysis. Some of these mutations,
homozygous deletions in particular, could be missed by Sanger
sequencing and a combination of methods may be required.50
In the family of dogs presented here, a full deletion of exon
10 was identified. This leads to a phenotype of similar severity to that
presented by the well-characterized Plott Hound dog model of MPS-I,
which is due to a G > A transition in the splicing site of intron 1, lead-
ing to the retention of the intron and creation of a premature stop
codon.51 In both dog models, the phenotype resembles more closely
to the human intermediate/attenuated form of MPS-I. The first abnor-
mality detected by the breeder of the dogs presented here was an
abnormal limb conformation and a stunted growth, which was first
noted by the age of 3 to 4 months. The main clinical signs were skele-
tal, cardiac and ocular as seen in the Plott Hound model.52 Facial
changes were also striking with a curved muzzle typically seen in
affected dogs53 and a mandibular prognatism, also described in
humans.54 Moreover, while no marked behavioral change was identi-
fied by the owner or the clinician, subtle neurological signs were
detected on neurological examination. Finally, the dog also reached
reproductive age. In human patients with 2 null variants of IDUA such
as a nonsense mutation or a large deletion, a severe phenotype is con-
sistently observed.43,46 This would suggest that the phenotype in the
dog models is attenuated compared to what would be expected in
humans suffering from nonsense mutations. A similar phenotype
attenuation has been discussed in the murine knock-out30 and spon-
taneous feline model,29 which also reached adulthood. This is an inter-
esting finding highlighting the limitations of animal models, which do
not always fully reproduce the human phenotype. The reason why
these animals do not suffer from a severe form remains unknown and
could be due to subtle variations in the metabolic rate of GAG
depending on the species.30 Understanding these interspecies differ-
ences could be an interesting subject of research, for which the estab-
lishment of a new dog research colony from these Golden retriever
dogs could prove helpful.
The main concern of the proband's owner was the recent onset
of gastrointestinal signs. Episodic diarrhea is also seen in many chil-
dren with Hurler's disease. Its etiology remains unknown although
abnormal intestinal flora has been suggested.55 The proband also
F IGURE 6 Integrated Genomics Viewer (IGV) display of the 30 end of the IDUA gene sequencing data of the affected dog. The lower panel of
the display shows the normal structure of the gene with the location of exons 3 to 14. In the affected dog, there is a deletion of the entire
exon 10
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suffered from renal agenesis. To the best of our knowledge, this has
never been described in people suffering from MPS-I and in this case
very likely represents an incidental and unrelated finding. However,
we cannot fully exclude that this could be a previously unseen sign.
Interestingly, histopathology revealed testicular changes, which is
poorly documented in people with MPS although testicular histopath-
ological changes were observed in a 19 year old man suffering from
MPS-II.56 Recently, male reproductive function was assessed in a
murine model of MPS-I. In these mice, tubular degeneration and disor-
ganization of the seminiferous epithelium with tubules containing very
few germ cells were observed histologically, similar to the findings
observed in this dog. Consistent with the histological findings, these
mice exhibited a marked reduction in the daily sperm production but
the plasma testosterone concentrations remained normal.57 The fact
that testosterone concentrations remain unchanged would explain the
benign prostatic hyperplasia seen in the proband.
Animal models of MPS-I have played an important role in the devel-
opment of therapies in humans. However, although hematopoietic stem
cell transplant (HSCT) and enzyme replacement therapy (ERT) have
improved the prognosis for these patients, there is still no cure and new
therapies such as gene therapies are still desperately sought.1,27,58-61
Dog models have been extremely valuable in the development of these
therapies over the last 3 decades62-67 and while generation of an IDUA
knock-out mouse has certainly increased the speed of research and
lowered the cost, studies on large animal models remain complementary.
Larger animal models such as cats and dogs have a longer life expec-
tancy, making it more appropriate to test therapeutics including their
potential complications in the long term.16,68 Their size and neuroanat-
omy (gyrencephalic vs lissencephalic brain) is also closer to that of a
young child, allowing better assessment of more advanced treatment
such as stereotaxic injections.53,68,69 In the present case, the prohibitive
cost of ERT precluded its use, all the more as weekly injections are typi-
cally required.28 Experimental treatment with PPS has recently been
shown to have a beneficial effect in the rat model of MPS-VI and dog
model of MPS-I, resulting in a marked reduction of the associated-
inflammation but also a reduction in the accumulation of GAG in the tis-
sues and urine.70-72 Although improvement of quality of life was
reported by the owner of the current dog after the treatment was initi-
ated, this remains subjective.
In conclusion, we have described a dog with MPS-I, which resem-
bles the attenuated form of the human disease. In this dog, the dis-
ease is secondary to a full deletion of the exon 10 of the IDUA gene,
leading to a deficiency in α-L-iduronidase activity. Contrary to what
would be expected in human patients with such a severe mutation,
the phenotype of this dog remained attenuated.
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